Clinical Trial Detail

NCT ID NCT02242097
Title Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

mantle cell lymphoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.